 Aldeyra Therapeutics, Inc. Nasdaq: ALDX Aldeyra, a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases, today announced development plans to support a New Drug Application NDA for the novel investigational reactive aldehyde species RASP inhibitor reproxalap in dry eye disease. Based on U.S. Food and Drug Administration FDA meeting minutes, Aldeyra intends to initiate two clinical trials to assess the activity of reproxalap in reducing tear levels of RASP, pro-inflammatory mediators recently accepted by the FDA as an objective sign of dry eye disease. 